{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:35:32Z","timestamp":1792204532017,"version":"4.4.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006484","name":"AbbVie Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jaad.2018.05.040","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T05:21:28Z","timestamp":1527830488000},"page":"60-69.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":177,"title":["Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study"],"prefix":"10.1016","volume":"80","author":[{"given":"Christos C.","family":"Zouboulis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin M.","family":"Okun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Errol P.","family":"Prens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gniadecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Lynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Weisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor B.E.","family":"Jemec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jaad.2018.05.040_bib1","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2018.05.040_bib2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11154-016-9328-5","article-title":"Evidence-based approach to the treatment of hidradenitis suppurativa\/acne inversa, based on the European guidelines for hidradenitis suppurativa","volume":"17","author":"Gulliver","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"issue":"2","key":"10.1016\/j.jaad.2018.05.040_bib3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000443878","article-title":"The ABC of hidradenitis suppurativa: a validated glossary on how to name lesions","volume":"232","author":"Lipsker","year":"2016","journal-title":"Dermatology"},{"issue":"2","key":"10.1016\/j.jaad.2018.05.040_bib4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000431175","article-title":"Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation","volume":"231","author":"Zouboulis","year":"2015","journal-title":"Dermatol"},{"key":"10.1016\/j.jaad.2018.05.040_bib5","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of IHS4, a novel dynamic scoring system to assess hidradenitis suppurativa\/acne inversa severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.05.040_bib6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-2230.1996.tb00145.x","article-title":"Hidradenitis suppurativa\u2014characteristics and consequences","volume":"21","author":"Jemec","year":"1996","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.05.040_bib7","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1046\/j.1365-2133.2001.04137.x","article-title":"Morbidity in patients with hidradenitis suppurativa","volume":"144","author":"von der Werth","year":"2001","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.05.040_bib8","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jaad.2009.09.021","article-title":"Hidradenitis suppurativa markedly decreases quality of life and professional activity [letter]","volume":"62","author":"Matusiak","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.05.040_bib9","unstructured":"Adalimumab [package insert]. AbbVie Inc. 2016. North Chicago, IL."},{"key":"10.1016\/j.jaad.2018.05.040_bib10","unstructured":"European Medicines Agency. Humira Adalimumab. Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000481\/human_med_000822.jsp&mid=WC0b01ac058001d124. Accessed June 30, 2018"},{"issue":"1","key":"10.1016\/j.jaad.2018.05.040_bib11","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/1744666X.2016.1221762","article-title":"Adalimumab for the treatment of hidradenitis suppurativa\/acne inversa","volume":"12","author":"Zouboulis","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2018.05.040_bib12","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2018.05.040_bib13","first-page":"5098","article-title":"Therapeutic response\u00a0guided dosing strategy to optimize long-term adalimumab treatment in patients with hidradenitis suppurativa: integrated results from the PIONEER phase 3 trials [abstract]","volume":"76","author":"Gulliver","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.05.040_bib14","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness, and meaningfulness of the hidradenitis suppurativa clinical response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.05.040_bib15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1365-2133.2003.05390.x","article-title":"Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa","volume":"149","author":"Sartorius","year":"2003","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.05.040_bib16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/sim.6343","article-title":"A PRIM approach to predictive-signature development for patient stratification","volume":"34","author":"Chen","year":"2015","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.jaad.2018.05.040_bib17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.lungcan.2015.09.011","article-title":"Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib","volume":"90","author":"McKeegan","year":"2015","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.jaad.2018.05.040_bib18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000365390","article-title":"Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data","volume":"230","author":"Basra","year":"2015","journal-title":"Dermatology"},{"issue":"suppl 3","key":"10.1016\/j.jaad.2018.05.040_bib19","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.12788\/j.sder.0092","article-title":"Natural history, presentation, and diagnosis of hidradenitis suppurativa","volume":"33","author":"Micheletti","year":"2014","journal-title":"Semin Cutan Med Surg"},{"issue":"4","key":"10.1016\/j.jaad.2018.05.040_bib20","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/bjd.13090","article-title":"Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study","volume":"171","author":"Kromann","year":"2014","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.05.040_bib21","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1046\/j.1468-3083.2000.00087.x","article-title":"The natural history of hidradenitis suppurativa","volume":"14","author":"von der Werth","year":"2000","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2018.05.040_bib22","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, and Crohn's disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218308363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218308363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:51:34Z","timestamp":1759272694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218308363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0190962218308363"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.05.040","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.05.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}